Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

9 Meters Biopharma, Inc. (NMTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2137-0.0112 (-4.98%)
At close: 04:00PM EDT
0.2161 +0.00 (+1.12%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2249
Open0.2299
Bid0.2130 x 1200
Ask0.2161 x 1200
Day's Range0.2100 - 0.2350
52 Week Range0.2100 - 1.4600
Volume10,119,781
Avg. Volume3,184,745
Market Cap55.371M
Beta (5Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.1680
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NMTR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 9 Meters Biopharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • American City Business Journals

    Chapel Hill company given extension to regain Nasdaq compliance

    A medical device company that set up shop in Chapel Hill last year has received some relief in its bid to remain listed on the Nasdaq Capital Market.

  • ACCESSWIRE

    9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

    Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel SyndromeRALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced it has entered into a senior secured convertible notes facility with a single lender for up to $70 million that is part of an overall financing strategy to support the continued develop

  • ACCESSWIRE

    9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

    (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), its Phase 2 trial of vurolenatide, a proprietary, long-acting GLP-1 receptor agonist in development for the treatment of adult patients with short bowel syndrome (SBS). Based on positive results from this Phase 2

Advertisement
Advertisement